Related Experiment Videos
Olanzapine-induced glucose dysregulation.
T L Bettinger1, S C Mendelson, P G Dorson
1College of Pharmacy, University of Texas at Austin, and Texas Department of Mental Health and Mental Retardation, 78712, USA.
The Annals of Pharmacotherapy
|August 6, 2000
Summary
Olanzapine therapy can cause severe type 2 diabetes exacerbation, even in patients with previously controlled glucose levels. Discontinuation of olanzapine led to improved blood glucose regulation in this case study.
Area of Science:
- Psychiatry and Endocrinology
- Pharmacology
- Metabolic Disorders
Background:
- Type 2 diabetes mellitus (T2DM) is a growing public health concern.
- Atypical antipsychotics, like olanzapine, are widely used for psychiatric conditions.
- Weight gain is a known side effect of atypical antipsychotics and a risk factor for T2DM.
Observation:
- A 54-year-old woman with diet-controlled T2DM experienced severe glucose dysregulation within 12 days of starting olanzapine.
- Despite aggressive management, her blood glucose remained unregulated, and she gained 13 kg.
- Discontinuation of olanzapine and quetiapine resulted in improved glycemic control.
Findings:
- Olanzapine therapy was associated with severe exacerbation of type 2 diabetes mellitus.
- Weight gain may not be the sole factor; serotonin (5-HT1A) antagonism is hypothesized to impair pancreatic beta-cell function.
- The Naranjo probability scale indicated a possible link between olanzapine and the observed glucose dysregulation.
Implications:
- Olanzapine, despite its benefits, may precipitate or worsen diabetes mellitus.
- Further research is needed to understand the incidence and mechanisms of olanzapine-induced glucose dysregulation.
- Clinicians should monitor glucose levels in patients initiating olanzapine therapy, especially those with pre-existing diabetes.